[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
July 20, 1994

Immunogenicity of Hepatitis B Vaccines

Author Affiliations

Hospital of Orleans Orleans, France

JAMA. 1994;272(3):202. doi:10.1001/jama.1994.03520030041020

To the Editor.  —Vaccination using a full course of three doses of HBV leads to the development of protective antibody to anti-HBs response in 85% to 95% of all vaccinees. A small proportion of vaccinees,1 however, fail to develop anti-HBs titers of greater than 10 mIU/mL, the minimal titer considered to be protective.2 Nonresponsiveness is thought to be associated with increasing age, obesity, smoking cigarettes, and certain immunogenetic status.Recently it has been reported that an important percentage of the nonresponders were positive for serum HBV DNA, detected by polymerase chain reaction. This was the case in four of six nonresponders in a study by Takahashi et al3 and in 16 of 26 in a study by Luo et al.4We studied nonresponders among health care workers in Hospital of Orleans (France). Each health care worker was vaccinated with three doses of recombinant vaccine (Engerix-B) at

First Page Preview View Large
First page PDF preview
First page PDF preview